Literature DB >> 20414778

Increased osteopontin-positive macrophage expression in colorectal cancer stroma with synchronous liver metastasis.

Motohiro Imano1, Kiyokata Okuno, Tatsuki Itoh, Eizaburo Ishimaru, Takao Satou, Hitoshi Shiozaki.   

Abstract

BACKGROUND: The macrophages that infiltrate the tumor stroma are termed tumor-associated macrophages (TAMs). TAMs contribute to hematogenous spread of cancer cells especially liver metastasis. Osteopontin (OPN) is also related to tumor metastasis and proliferation of tumors. OPN is mainly expressed in macrophages of stroma other than that of tumor cells. The aim of the present study was to investigate differences in OPN-positive TAMs between cases of colorectal cancer with synchronous liver metastasis and those without liver metastasis.
METHODS: A total of 54 subjects who had undergone resection of a primary tumor of advanced colorectal cancer were classified into two groups: synchronous colorectal liver metastasis group (s-CLM group; n = 30) and no liver metastasis group (controls; n = 24). The number of OPN- and CD68-positive cells and the microvascular density (MVD) were determined using the CD105 antibody in the stroma of the invasive margin of the tumor and in the stroma of the central area.
RESULTS: There was no difference in the patient profiles between the two groups. OPN and MVD expression in the central area were significantly higher in the s-CLM group (OPN: control 4.3 +/- 1.42, s-CML 12.1 +/- 1.42, P < 0.05; MVD: control 18.5 +/- 2.86, s-CML 27.5 +/- 2.94, P < 0.05), whereas CD68 expression in the invasive margin was significantly higher in the control group (control 98.9 +/- 7.31, s-CML 29.0 +/- 4.44, P < 0.05).
CONCLUSIONS: These data suggest that OPN in the central area may have induced high microvascular density, which led to liver metastasis. Thus, OPN might be a potential target for novel antiangiogenesis therapy for treating colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20414778     DOI: 10.1007/s00268-010-0582-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  48 in total

Review 1.  Tumor interactions with the vasculature: angiogenesis and tumor metastasis.

Authors:  C H Blood; B R Zetter
Journal:  Biochim Biophys Acta       Date:  1990-06-01

2.  Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.

Authors:  N Shijubo; T Uede; S Kon; M Maeda; T Segawa; A Imada; M Hirasawa; S Abe
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

3.  Placental growth factor is a survival factor for tumor endothelial cells and macrophages.

Authors:  Avner Adini; Tad Kornaga; Farshid Firoozbakht; Laura E Benjamin
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

4.  Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays.

Authors:  M N Bobrow; T D Harris; K J Shaughnessy; G J Litt
Journal:  J Immunol Methods       Date:  1989-12-20       Impact factor: 2.303

5.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.

Authors:  N Weidner; P R Carroll; J Flax; W Blumenfeld; J Folkman
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

6.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

7.  Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator.

Authors:  C R Berney; J L Yang; R J Fisher; P J Russell; P J Crowe
Journal:  Anticancer Res       Date:  1998 Mar-Apr       Impact factor: 2.480

Review 8.  Osteopontin: a protein with diverse functions.

Authors:  D T Denhardt; X Guo
Journal:  FASEB J       Date:  1993-12       Impact factor: 5.191

9.  Osteopontin expression in a group of lymph node negative breast cancer patients.

Authors:  A B Tuck; F P O'Malley; H Singhal; J F Harris; K S Tonkin; N Kerkvliet; Z Saad; G S Doig; A F Chambers
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

10.  Immunohistochemical expression of osteopontin in gastric cancer.

Authors:  Motohiro Imano; Takao Satou; Tatsuki Itoh; Kenichi Sakai; Eizaburo Ishimaru; Atsushi Yasuda; Ying-Feng Peng; Masayuki Shinkai; Fumiharu Akai; Takushi Yasuda; Haruhiko Imamoto; Kiyokata Okuno; Hiroyuki Ito; Hitoshi Shiozaki; Harumasa Ohyanagi
Journal:  J Gastrointest Surg       Date:  2009-07-07       Impact factor: 3.452

View more
  3 in total

1.  Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin.

Authors:  Jaimie Chang; Swati S Bhasin; Diane R Bielenberg; Vikas P Sukhatme; Manoj Bhasin; Sui Huang; Mark W Kieran; Dipak Panigrahy
Journal:  FASEB J       Date:  2018-06-29       Impact factor: 5.191

2.  The role of tumour stroma in colorectal cancer invasion and metastasis.

Authors:  John Conti; Gareth Thomas
Journal:  Cancers (Basel)       Date:  2011-04-26       Impact factor: 6.639

3.  Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia.

Authors:  Naoyoshi Maeda; Takashi Ohashi; Haorile Chagan-Yasutan; Toshio Hattori; Yayoi Takahashi; Hideo Harigae; Hiroo Hasegawa; Yasuaki Yamada; Masahiro Fujii; Katsumi Maenaka; Toshimitsu Uede
Journal:  Retrovirology       Date:  2015-11-24       Impact factor: 4.602

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.